BSEBoard Meeting4d ago · 8 Aug 2026, 03:10 pm

Panacea Biotec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve Standalone and Consolidated ....

Panacea Biotec Ltd · 531349

✦ AI SummaryResults

Panacea Biotec Ltd has scheduled a Board Meeting on August 13, 2026, to consider and approve the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter ended June 30, 2026.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Panacea Biotec Ltd - 531349 - Board Meeting Intimation for Inter-Alia, Approval Of Standalone And Consolidated Unaudited Financial Results (Provisional) For The Quarter Ended June 30, 2026

Attachments (1)

📄

8578b095-f802-4408-95bb-10b41117a3ec.pdf

pdf

Download →
View document text
August 08, 2026 The Manager, Listing Department BSE Limited The National Stock Exchange of India Ltd. Corporate Relationship Department, Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (E), Mumbai - 400 051 Dalal Street, Mumbai - 400 001 NSE Symbol: PANACEABIO BSE Scrip Code: 531349 Reg.: Board Meeting on August 13, 2026, to approve Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter ended June 30, 2026 Dear Sir / Madam, Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), this is to inform you that: (i) the meeting of the Board of Directors of the Company is scheduled to be held on Thursday, August 13, 2026, at New Delhi, inter-alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter ended June 30, 2026; (ii) pursuant to Regulation 46(2) of the SEBI LODR Regulations, notice of the said meeting is also being uploaded on the website of the Company; and (iii) with reference to our earlier announcement dated June 26, 2026 intimating the Closure of Trading Window pursuant to the Company's Code of Conduct for Prevention of Insider Trading framed in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, the trading window of the Company shall remain closed for all Designated Persons (including their Immediate Relatives) of the Company from July 01, 2026 till August 15, 2026. This is for your kind information and record please. Thanking you, Sincerely yours, For Panacea Biotec Limited Ankit Jain General Manager - Legal & Company Secretary Panacea Biotec Limited (CIN: L33117PB1984PLC022350) Regd. Office : Ambala Chandigarh Highway, Lalru – 140501, Punjab Correspondence/Corporate office : B-1 Extn../G-3, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India Ph.: 91-11-4167 9000, 4167 8000, Fax: 91-11-4167 9070 Email: companysec@panaceabiotec.com